BACKGROUND: Antibodies produced in response to infection with any of the four serotypes of dengue virus generally provide homotypic immunity. However, prior infection or circulating maternal antibodies can also mediate a non-protective antibody response that can enhance the course of disease in a subsequent heterotypic infection. Naturally occurring human monoclonal antibodies can help us understand the protective and pathogenic roles of the humoral immune system in dengue virus infection. RESULTS: Epstein-Barr Virus (EBV) transformation of B cells isolated from the peripheral blood of a human subject with previous dengue infection was performed. B cell cultures were screened by ELISA for antibodies to dengue (DENV) envelope (E) protein. ELISA positive cultures were cloned by limiting dilution. Three IgG1 human monoclonal antibodies (HMAbs) were purified and their binding specificity to E protein was verified by ELISA and biolayer interferometry. Neutralization and enhancement assays were conducted in epithelial and macrophage-like cell lines, respectively. All three HMAbs bound to E from at least two of the four DENV serotypes, one of the HMAbs was neutralizing, and all were able to enhance DENV infection. CONCLUSIONS: HMAbs against DENV can be successfully generated by EBV transformation of B cells from patients at least two years after naturally acquired DENV infections. These antibodies show different patterns of cross-reactivity, neutralizing, and enhancement activity.
BACKGROUND: Antibodies produced in response to infection with any of the four serotypes of dengue virus generally provide homotypic immunity. However, prior infection or circulating maternal antibodies can also mediate a non-protective antibody response that can enhance the course of disease in a subsequent heterotypic infection. Naturally occurring human monoclonal antibodies can help us understand the protective and pathogenic roles of the humoral immune system in dengue virus infection. RESULTS: Epstein-Barr Virus (EBV) transformation of B cells isolated from the peripheral blood of a human subject with previous dengue infection was performed. B cell cultures were screened by ELISA for antibodies to dengue (DENV) envelope (E) protein. ELISA positive cultures were cloned by limiting dilution. Three IgG1 human monoclonal antibodies (HMAbs) were purified and their binding specificity to E protein was verified by ELISA and biolayer interferometry. Neutralization and enhancement assays were conducted in epithelial and macrophage-like cell lines, respectively. All three HMAbs bound to E from at least two of the four DENV serotypes, one of the HMAbs was neutralizing, and all were able to enhance DENVinfection. CONCLUSIONS:HMAbs against DENV can be successfully generated by EBV transformation of B cells from patients at least two years after naturally acquired DENV infections. These antibodies show different patterns of cross-reactivity, neutralizing, and enhancement activity.
Authors: Shi-Hua Xiang; Najah Doka; Rabeéa K Choudhary; Joseph Sodroski; James E Robinson Journal: AIDS Res Hum Retroviruses Date: 2002-11-01 Impact factor: 2.205
Authors: K S Cole; M Alvarez; D H Elliott; H Lam; E Martin; T Chau; K Micken; J L Rowles; J E Clements; M Murphey-Corb; R C Montelaro; J E Robinson Journal: Virology Date: 2001-11-10 Impact factor: 3.616
Authors: Anuja Mathew; Kim West; Siripen Kalayanarooj; Robert V Gibbons; Anon Srikiatkhachorn; Sharone Green; Daniel Libraty; Smita Jaiswal; Alan L Rothman Journal: J Infect Dis Date: 2011-09-19 Impact factor: 5.226
Authors: Bimmi Shrestha; S Kyle Austin; Kimberly A Dowd; Abhishek N Prasad; Soonjeon Youn; Theodore C Pierson; Daved H Fremont; Gregory D Ebel; Michael S Diamond Journal: Virology Date: 2012-03-09 Impact factor: 3.616
Authors: Katherine L Williams; Wahala M P B Wahala; Susana Orozco; Aravinda M de Silva; Eva Harris Journal: Virology Date: 2012-04-25 Impact factor: 3.616
Authors: Joanna L Miller; Ruben Lachica; Andrew C Sayce; James P Williams; Manisha Bapat; Raymond Dwek; P Robert Beatty; Eva Harris; Nicole Zitzmann Journal: Antimicrob Agents Chemother Date: 2012-10-15 Impact factor: 5.191
Authors: Smita Jaiswal; Kenneth Smith; Alejandro Ramirez; Marcia Woda; Pamela Pazoles; Leonard D Shultz; Dale L Greiner; Michael A Brehm; Anuja Mathew Journal: Exp Biol Med (Maywood) Date: 2014-08-14
Authors: Joshua M Costin; Ekachai Jenwitheesuk; Shee-Mei Lok; Elizabeth Hunsperger; Kelly A Conrads; Krystal A Fontaine; Craig R Rees; Michael G Rossmann; Sharon Isern; Ram Samudrala; Scott F Michael Journal: PLoS Negl Trop Dis Date: 2010-06-22
Authors: Joshua M Costin; Elena Zaitseva; Kristen M Kahle; Cindo O Nicholson; Dawne K Rowe; Amanda S Graham; Lindsey E Bazzone; Greg Hogancamp; Marielys Figueroa Sierra; Rachel H Fong; Sung-Tae Yang; Li Lin; James E Robinson; Benjamin J Doranz; Leonid V Chernomordik; Scott F Michael; John S Schieffelin; Sharon Isern Journal: J Virol Date: 2012-10-17 Impact factor: 5.103